INFORMATION DISCLOSURE CITATION

Atty. Docket No.	8576.0012-01	Appln. No Unassigned.	
Applicant	Cara A. PELLEGRINI et al.		<u>:</u>
Filing Date	August XX, 2003	Group:	Unassigned

	U.S. PATENT DOCUMENTS							
Examiner Initial*	T	Document Number	Issue Date Name		Cla ss	Sub Class	Filing Date If Appropriate	
/A.S./	T	3,843,668	10/22/74)/22/74 Neumann				
	Τ	4,053,617	10/11/77	Eichenberger et al.				
	T	5,837,285	Nov. 17, 1998	Nakamichi et al.	424	464		
	T	5,977,175	Nov. 2, 1999	Lin	514	558	·	
	T	5,980,927	11/9/99	Nelson et al.				
		6,110,494	Aug. 29, 2000	Clancy et al.	424	461		
	T	6,143,325	Nov. 7, 2000	Dennis et al.	424	468		
	T	6,214,370	4/10/01	Nelson et al.				
		6,248,363 B1	Jun. 19, 2001	Patel et al.	424	497		
	T	6,268,389 B1	Jul. 31, 2001	Esser et al.	514	398		
	T	6,342,245 B1	Jan. 29, 2002	Baert et al.	424	451	April 24, 2000	
	T	2001/0007678A1	Jul. 12, 2001	Baert et al.	424	464		
	T	2001/0024659A1	Sep. 27, 2001	Chen et al.	424	457		
$\overline{}$	1	2002/0006919A1	Jan. 17, 2002	Thosar et al.	514	175		

		FOREIGN PATEN	IT DOCUMENTS	S		
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
П						

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
/A.S./	"Tizanidine," http://www.virtualdrugstore.com/ms/tizanidine.html						
1	"Pharmacology," http://www.southshoreneurologic.com/spas-manag/spas-pharmacology.html						
	"Spasticity," http://www.wemove.org/spa.mtop.html						
	Wagstaff et al., Tizanidine, "A Review of its Pharmacology, Clinical Efficacy and Tolerability in the Management of Spasticity Associated with Cerebral and Spinal Disorders," ADIS Drug Evaluation, Drugs, 53(3), pp. 435-452 (March 1997)						
V	Zanaflex®, 2001 Physicians' Desk Reference (2001)						

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	8576.0012-01	Appln. No Unassigned.		
Applicant	Cara A. PELLEGRINI et al.			•
Filing Date	August XX, 2003	Group:	Unassigned	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
/A.S./	The Merck Index (1989)				
	Wesnes et al., "Effects of Sibutramine alone and with alcohol on cognitive function in healthy volunteers," <i>British Journal of Clinical Pharmacology</i> , 49, pp. 110-117 (2000)				
	Simpson et al., "The Cognitive Drug Research Computerized Assessment System for Demented Patients: A Validation Study, International Journal of Geriatric Psychiatry," International Journal of Geriatric Psychiatry, Vol. 6, pp. 95-102 (1991)				
	Chapleo et al., "Heteroaromatic Analogues of the α ₂ -Adrenoreceptor Partial Agonist Clonidine," <i>J. Med. Chem</i> , 32, pp. 1627-1630 (1989)				
	Smith et al., "Tizanidine in the management of spasticity and musculoskeletal complaints in the palliative care population, American Journal of Hospice & Palliative Care," American Journal of Hospice & Palliative Care, 17(1), pp. 50-58 (Jan-Feb. 2000)				
	Hutchinson, D. E., Modified Release of Tizanidine, A Review; Volume 17, No. 5 pp. 565-573 (1989)				
	Holtebeck, B., "Tizanidine: An alternative in the Pharmacologic Treatment of Spasticity," <u>Journal of the Pharmacy Society of Wisconsin</u> , Mar/Apr 2000: 26-31 (2000).				
	Young, R., "Tizanidine and spasticity," Neurology 45(12): 2296-2296 (1995).				
	Roberts, R.C., et al., "Pharmacokinetics and pharmacodynamics of tizanidine," Neurology 44(Supple): S29-S31 (1994).				
	Wallace, J.D., "Summary of combined clinical trials analysis of controlled clinical trials with tizanidine," Neurology 44(Supp 9): S60-S68 (1994).				
$\overline{\mathbf{V}}$	Shellenberger, M.K., et al., "A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state," <u>Drug Metabolism and Distribution</u> 27(2): 201-204 (1999).				

Examiner	/Ali Soroush/	Date Considered 06/07/2007				
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					
Form PTO 14	49 Patent and	d Trademark Office - U.S. Department of Con	nmerce			

IDS Form	PTO/SB/08: Substitute for fo	orm 1449A/PTO			Complete if Known	OIPE	7
				Application Number	10/645,840	7	
	INFORMATION I	DISCLOSII	RF	Filing Date	August 22. 2003		~~~
				First Named Inventor	Cara A. PELLEGRINI	MAY Z 5 Z	COUS E
	STATEMENT BY	APPLICA	Ni	Art Unit	1614	Ž	3
	(Use as many sheet	is as necessary)		Examiner Name	Unknown	(A)	-8t
Sher	at 1	of	1	Attorney Docket Number	9762-0001-01	PRADE	

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS								
Examiner	Cite	Document Number	Issue or	Name of Patentee or	Pages, Columns, Lines, Where			
Initials	No.'	Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			
A.S./		US-6,455,557 B1	09-24-2002	Pellegrini et al.				
A.S./		US-6,407,128	06-18-2002	Scaife et al.				

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶	
_							
			_				

-		NON PATENT LITERATURE DOCUMENTS	Translation ⁶
Examiner Initials No.'		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		ROWLAND, M.B., et al., Absorption, Clinical Pharmacokinetics: Concepts and Applications, pp. 16-33 (1980). (As described and provided by the International Searching Authority)	
		CHARMAN, W.N., et al., Physicochemical and Physiological Mechanisms for the Effects of Food on Drug Absorption: The Role of Lipids and pH, J. Pharmaceutical Sciences, Vol. 86, No. 3, pp. 269-282 (March 1997). (As described and provided by the International Searching Authority)	
		EMRE M., et al., Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud®), J. of Neurology, Neurosurgery and Psychiatry, Vol. 57, pp. 1355-1359 (1994). (As described and provided by the International Searching Authority)	
		MURAKAMI, K., et al., Clinical Evaluation of Tizanidine on masticatory myofascial pain and temporomandibular dysfunction, Oral Therapeutics and Pharmacology, Vol. 14, No. 1, pp. 39-46 (1995). (Abstract as described and provided by the International Searching Authority)	
V		International Search Report and Written Opinion for PCT/US/2004/024390, dated December 8, 2004.	

Examiner	140.0	Date	06/07/2007
Signature	/Ali Soroush/	Considered	00/07/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.